Comparison of Surgery and Active Surveillance in the Treatment of Bosniak III Renal Cysts
Primary Purpose
Cystic Renal Disease, Kidney Cancer, Surgery
Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Delayed surgery
Immediate surgery
Sponsored by
About this trial
This is an interventional treatment trial for Cystic Renal Disease focused on measuring Bosniak classification, Active surveillance, Renal cystic mass, Cystic renal cell carcinoma
Eligibility Criteria
Inclusion Criteria:
- A sporadic single CM of Bosniak 3 according to the Bosniak Classification v.2019 is diagnosed with CT or MRI
- Maximal diameter of CM 10-70 mm
- Age ≥50 years
- ECOG performance status <2
- Life expectancy ≥5 years
- Patient is fit to undergo surgery and AS.
- Patient understands a national language or English
- Signed informed consent
Exclusion Criteria:
- Genetic syndromes associated with RCC
- Previously or simultaneously diagnosed and pathologically verified RCC
- Previously or simultaneously radiographically identified solid mass or CM of Bosniak 3/4 with diameter ≥10mm
- The target CM of Bosniak 3 has progressed in sequential imaging from Bosniak 1-2F
- Presence of radiographic findings which are suspect for nodal or distant metastatic disease
- Symptomatic CM
- Kidney insufficiency (GFR<55 ml/min/1,73m2)
- Patients who have contraindications for both CT and MRI imaging. . Anatomically solitary kidney
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
Immediate surgery
Active surveillance
Arm Description
Patients undergo excision of a renal mass by partial or radical nephrectomy and will be followed by UISS risk classification.
Patients enter active surveillance protocol. Delayed surgery on active surveillance will be recommended if progression from Bosniak 3 to 4 or a solid mass is noted on imaging by radiologist
Outcomes
Primary Outcome Measures
Malignancy rate in surgical pathology
Secondary Outcome Measures
Cancer specific survival
Progression-free survival
Overall survival
Full Information
NCT ID
NCT04670887
First Posted
November 26, 2020
Last Updated
February 16, 2021
Sponsor
Helsinki University Central Hospital
1. Study Identification
Unique Protocol Identification Number
NCT04670887
Brief Title
Comparison of Surgery and Active Surveillance in the Treatment of Bosniak III Renal Cysts
Official Title
A Prospective Multicenter Trial Comparing Surgery Versus Active Surveillance In Patients With Bosniak 3 Renal Cystic Masses, A NoRenCa And FinnKidney Study
Study Type
Interventional
2. Study Status
Record Verification Date
December 2020
Overall Recruitment Status
Not yet recruiting
Study Start Date
March 15, 2021 (Anticipated)
Primary Completion Date
January 11, 2024 (Anticipated)
Study Completion Date
January 11, 2036 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Helsinki University Central Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The incidence of renal cysts is rising due to increased abdominal imaging. Renal complicated cysts have been traditionally classified according to the Bosniak classification, which distinguishes cystic masses by specific features of walls and septa. The categories I and II are benign and class IIF most probably benign but needs a short radiological follow-up. Categories III and IV have been traditionally operated due to the increased risk of renal cell carcinoma. However, recently published studies show that approximately 50% of the operated Bosniak III cystic masses are benign, which means that half of the cases are overtreated by surgery. It has also been shown that surgical pathology of stable Bosniak IIF cysts is malignant in less than 1%, while the cysts, which are upgraded to higher Bosniak classes will show malignant surgical pathology in 85%. So far, there is lack of prospective data on active surveillance in Bosniak III cystic masses.
The aim of the study is to compare active surveillance and surgery in patients with Bosniak III renal cystic masses. Patients will be randomized in active surveillance or immediate surgical excision of a cystic mass. In the active surveillance group, patients are followed according to the study protocol for 10 years and treated with delayed surgery if the cystic mass upgrades into Bosniak IV/solid, becomes symptomatic or grows over a preclassified threshold. The primary objective is to compare surgical pathology between patients treated with immediate surgery versus delayed surgery.
According to recent retrospective data, active surveillance of Bosniak III cystic masses is reasonable and oncologically safe. Therefore a prospective randomized controlled trial is needed to get high level evidence to support a change in the treatment strategy. The study may significantly reduce unnecessary operations performed in patients with Bosniak III cystic masses.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cystic Renal Disease, Kidney Cancer, Surgery
Keywords
Bosniak classification, Active surveillance, Renal cystic mass, Cystic renal cell carcinoma
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
200 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Immediate surgery
Arm Type
Active Comparator
Arm Description
Patients undergo excision of a renal mass by partial or radical nephrectomy and will be followed by UISS risk classification.
Arm Title
Active surveillance
Arm Type
Active Comparator
Arm Description
Patients enter active surveillance protocol. Delayed surgery on active surveillance will be recommended if progression from Bosniak 3 to 4 or a solid mass is noted on imaging by radiologist
Intervention Type
Procedure
Intervention Name(s)
Delayed surgery
Intervention Description
Delayed surgery is performed if cystic mass radiologically upgrades into Bosniak 4 or solid mass in the active surveillance.
Intervention Type
Procedure
Intervention Name(s)
Immediate surgery
Intervention Description
Partial or radical nephrectomy is performed as treatment of Bosniak 3 cystic mass
Primary Outcome Measure Information:
Title
Malignancy rate in surgical pathology
Time Frame
From date of randomization until the date of surgery, assessed up to 120 months
Secondary Outcome Measure Information:
Title
Cancer specific survival
Time Frame
From date of randomization until the date of death due to renal cancer, assessed up to 120 months
Title
Progression-free survival
Time Frame
From date of randomization until the date of first documented progression, assessed up to 120 months
Title
Overall survival
Time Frame
From date of randomization until the date of death from any cause, assessed up to 120 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
50 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
A sporadic single CM of Bosniak 3 according to the Bosniak Classification v.2019 is diagnosed with CT or MRI
Maximal diameter of CM 10-70 mm
Age ≥50 years
ECOG performance status <2
Life expectancy ≥5 years
Patient is fit to undergo surgery and AS.
Patient understands a national language or English
Signed informed consent
Exclusion Criteria:
Genetic syndromes associated with RCC
Previously or simultaneously diagnosed and pathologically verified RCC
Previously or simultaneously radiographically identified solid mass or CM of Bosniak 3/4 with diameter ≥10mm
The target CM of Bosniak 3 has progressed in sequential imaging from Bosniak 1-2F
Presence of radiographic findings which are suspect for nodal or distant metastatic disease
Symptomatic CM
Kidney insufficiency (GFR<55 ml/min/1,73m2)
Patients who have contraindications for both CT and MRI imaging. . Anatomically solitary kidney
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Harry Nisén, Adj. professor
Phone
+35894711
Email
harry.nisen@hus.fi
First Name & Middle Initial & Last Name or Official Title & Degree
Juhana Rautiola
Phone
+35894711
Email
juhana.rautiola@hus.fi
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Harry Nisén
Organizational Affiliation
Helsinki University Central Hospital
Official's Role
Principal Investigator
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
All IPD that underlie results in a publication.
IPD Sharing Time Frame
Starting 6 months after publication.
IPD Sharing Access Criteria
Requests are reviewed by the steering committee.
Learn more about this trial
Comparison of Surgery and Active Surveillance in the Treatment of Bosniak III Renal Cysts
We'll reach out to this number within 24 hrs